Jubilant Ingrevia Limited (JUBLINGREA.NS)
INR 800.95
(-4.21%)
INR 800.95
(-4.21%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.56 Billion INR | -27.45% |
| 2022 | 5.8 Billion INR | -33.19% |
| 2021 | 8.63 Billion INR | 627.87% |
| 2020 | 1.06 Billion INR | 72012.65% |
| 2019 | -1.66 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 1.34 Billion INR | 23.15% |
| 2024 Q1 | 1.09 Billion INR | 8.73% |
| 2023 Q2 | 1.26 Billion INR | 0.98% |
| 2023 FY | - INR | -27.45% |
| 2023 Q4 | 912.4 Million INR | -12.59% |
| 2023 Q3 | 1.04 Billion INR | -17.36% |
| 2023 Q1 | 1.25 Billion INR | 12.61% |
| 2022 Q2 | 1.6 Billion INR | 6.09% |
| 2022 Q1 | 1.5 Billion INR | 2.21% |
| 2022 FY | - INR | -33.19% |
| 2022 Q4 | 1.11 Billion INR | -29.84% |
| 2022 Q3 | 1.58 Billion INR | -1.17% |
| 2021 FY | - INR | 627.87% |
| 2021 Q4 | 1.47 Billion INR | -33.46% |
| 2021 Q3 | 2.21 Billion INR | 9.75% |
| 2021 Q2 | 2.02 Billion INR | -29.64% |
| 2021 Q1 | 2.87 Billion INR | 240.72% |
| 2020 Q4 | 843.74 Million INR | 220.42% |
| 2020 Q3 | -700.65 Million INR | -130.43% |
| 2020 Q2 | 2.3 Billion INR | 0.0% |
| 2020 FY | - INR | 72012.65% |
| 2019 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Biocon Limited | 41.52 Billion INR | 89.009% |
| Blue Jet Healthcare Limited | 2.29 Billion INR | -99.111% |
| Concord Biotech Limited | 4.65 Billion INR | 2.036% |
| Dishman Carbogen Amcis Limited | 3.07 Billion INR | -48.585% |
| Lyka Labs Limited | 167.58 Million INR | -2623.466% |
| Panacea Biotec Limited | -47.58 Million INR | 9692.749% |
| Piramal Pharma Limited | 13.05 Billion INR | 65.04% |
| SMS Lifesciences India Limited | 349.41 Million INR | -1206.268% |
| Supriya Lifescience Limited | 1.83 Billion INR | -148.629% |
| Syngene International Limited | 10.84 Billion INR | 57.922% |
| TAKE Solutions Limited | -1.05 Billion INR | 534.341% |
| Zota Health Care Limited | 82.07 Million INR | -5461.183% |